Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b polysaccharide–tetanus protein conjugate (Hib-TT)
- Target
- Hib-TT
- Molecular classification
- Biotech/biologic, Inactivated / Conjugate Vaccine, Toxoid-based, Polysaccharide, Protein
01
Overview
The Haemophilus influenzae type b (Hib) polysaccharide–tetanus protein conjugate is a vaccine antigen used to prevent invasive diseases caused by the bacterium *Haemophilus influenzae* type b, such as meningitis, epiglottitis, and sepsis. The vaccine is composed of the capsular polysaccharide from Hib (specifically polyribosyl-ribitol-phosphate, PRP) covalently linked to tetanus toxoid as a carrier protein. The conjugate vaccine induces a strong IgG response via T-dependent pathway enabling infants and young children to mount a robust immune response. Vaccination induces high levels of anti-PRP IgG antibodies with demonstrated bactericidal activity against Hib.
- Other names
- Haemophilus influenzae type B strain 1482 capsular polysaccharide–inactivated tetanus toxoid conjugate vaccineActHIB antigen
02
Mechanism of action
Induces strong IgG response via T-dependent pathway leading to production of anti-PRP antibodies.
03
Biological functions
Immune responseAntigen presentationB cell activationAntibody productionImmunization
04
Disease associations
InfectionHaemophilus influenzae type b infectionMeningitisEpiglottitisSepsis
05
Biomarkers
Anti-PRP IgG antibody titer (>= 1.0 mcg/mL correlates with long-term protection)
Beyond the preview
Go deeper on Haemophilus influenzae type b polysaccharide–tetanus protein conjugate (Hib-TT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b polysaccharide–tetanus protein conjugate (Hib-TT).